Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial

B. J. Hansen; J. Nordling; H. J A Mensink; S. Walter; H. H. Meyhoff; J. A F Leenarts; J. K. Oosten; F. F. Van Soest; G. A. Dijkman; J. W. Hoekstra; N. J W Van Baasbank; R. T. Bijleveld; P. F C M Braam; T. J M Schlatmann; J. Felderhof; G. S S Khoe; P. Dik; H. J A Mensink; J. Skov

Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial

B. J. Hansen^*, J. Nordling, H. J A Mensink, S. Walter, H. H. Meyhoff, J. A F Leenarts, J. K. Oosten, F. F. Van Soest, G. A. Dijkman, J. W. Hoekstra, N. J W Van Baasbank, R. T. Bijleveld, P. F C M Braam, T. J M Schlatmann, J. Felderhof, G. S S Khoe, P. Dik, H. J A Mensink, J. Skov

^*Corresponding author for this work

Department of Radiotherapy

Research output: Contribution to journal › Article › Academic › peer-review

46 Citations (Scopus)

Abstract

In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia(BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2,5 mg TID or placebo TID during 12 weeks. After 12 weeks symptom scores assessed according to the Madsen-Iversen scale were significantly reduced in the alfuzosin group and peak flow rate significantly increased compared to the placebo group. There were no significant differences concerning adverse events or withdrawals. Alfuzosin proved to have a beneficial effect in patients with symptomatic BPH with few and minor adverse events.

Original language	English
Pages (from-to)	169-175
Number of pages	7
Journal	Scandinavian Journal of Urology and Nephrology, Supplement
Issue number	157
Publication status	Published - 4 Jul 1994

Keywords

alfuzosin
BPH
symptom score

Cite this

Hansen, B. J., Nordling, J., Mensink, H. J. A., Walter, S., Meyhoff, H. H., Leenarts, J. A. F., Oosten, J. K., Van Soest, F. F., Dijkman, G. A., Hoekstra, J. W., Van Baasbank, N. J. W., Bijleveld, R. T., Braam, P. F. C. M., Schlatmann, T. J. M., Felderhof, J., Khoe, G. S. S., Dik, P., Mensink, H. J. A., & Skov, J. (1994). Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scandinavian Journal of Urology and Nephrology, Supplement, (157), 169-175.

@article{469fa47f72e647f78aeae25a2f2cde7c,

title = "Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial",

abstract = "In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia(BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2,5 mg TID or placebo TID during 12 weeks. After 12 weeks symptom scores assessed according to the Madsen-Iversen scale were significantly reduced in the alfuzosin group and peak flow rate significantly increased compared to the placebo group. There were no significant differences concerning adverse events or withdrawals. Alfuzosin proved to have a beneficial effect in patients with symptomatic BPH with few and minor adverse events.",

keywords = "alfuzosin, BPH, symptom score",

author = "Hansen, {B. J.} and J. Nordling and Mensink, {H. J A} and S. Walter and Meyhoff, {H. H.} and Leenarts, {J. A F} and Oosten, {J. K.} and {Van Soest}, {F. F.} and Dijkman, {G. A.} and Hoekstra, {J. W.} and {Van Baasbank}, {N. J W} and Bijleveld, {R. T.} and Braam, {P. F C M} and Schlatmann, {T. J M} and J. Felderhof and Khoe, {G. S S} and P. Dik and Mensink, {H. J A} and J. Skov",

year = "1994",

month = jul,

day = "4",

language = "English",

pages = "169--175",

number = "157",

}

Hansen, BJ, Nordling, J, Mensink, HJA, Walter, S, Meyhoff, HH, Leenarts, JAF, Oosten, JK, Van Soest, FF, Dijkman, GA, Hoekstra, JW, Van Baasbank, NJW, Bijleveld, RT, Braam, PFCM, Schlatmann, TJM, Felderhof, J, Khoe, GSS, Dik, P, Mensink, HJA & Skov, J 1994, 'Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial', Scandinavian Journal of Urology and Nephrology, Supplement, no. 157, pp. 169-175.

Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. / Hansen, B. J.; Nordling, J.; Mensink, H. J A et al.
In: Scandinavian Journal of Urology and Nephrology, Supplement, No. 157, 04.07.1994, p. 169-175.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Alfuzosin in the treatment of benign prostatic hyperplasia

T2 - Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial

AU - Hansen, B. J.

AU - Nordling, J.

AU - Mensink, H. J A

AU - Walter, S.

AU - Meyhoff, H. H.

AU - Leenarts, J. A F

AU - Oosten, J. K.

AU - Van Soest, F. F.

AU - Dijkman, G. A.

AU - Hoekstra, J. W.

AU - Van Baasbank, N. J W

AU - Bijleveld, R. T.

AU - Braam, P. F C M

AU - Schlatmann, T. J M

AU - Felderhof, J.

AU - Khoe, G. S S

AU - Dik, P.

AU - Mensink, H. J A

AU - Skov, J.

PY - 1994/7/4

Y1 - 1994/7/4

N2 - In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia(BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2,5 mg TID or placebo TID during 12 weeks. After 12 weeks symptom scores assessed according to the Madsen-Iversen scale were significantly reduced in the alfuzosin group and peak flow rate significantly increased compared to the placebo group. There were no significant differences concerning adverse events or withdrawals. Alfuzosin proved to have a beneficial effect in patients with symptomatic BPH with few and minor adverse events.

AB - In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia(BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2,5 mg TID or placebo TID during 12 weeks. After 12 weeks symptom scores assessed according to the Madsen-Iversen scale were significantly reduced in the alfuzosin group and peak flow rate significantly increased compared to the placebo group. There were no significant differences concerning adverse events or withdrawals. Alfuzosin proved to have a beneficial effect in patients with symptomatic BPH with few and minor adverse events.

KW - alfuzosin

KW - BPH

KW - symptom score

UR - http://www.scopus.com/inward/record.url?scp=0028188760&partnerID=8YFLogxK

M3 - Article

C2 - 7524141

AN - SCOPUS:0028188760

SN - 0300-8886

SP - 169

EP - 175

JO - Scandinavian Journal of Urology and Nephrology, Supplement

JF - Scandinavian Journal of Urology and Nephrology, Supplement

IS - 157

ER -

Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial

Abstract

Keywords

Other files and links

Fingerprint

Cite this